208 related articles for article (PubMed ID: 28681160)
1. Biopharmaceutical Evaluation and CMC Aspects of Oral Modified Release Formulations.
Chang RK; Mathias N; Hussain MA
AAPS J; 2017 Sep; 19(5):1348-1358. PubMed ID: 28681160
[TBL] [Abstract][Full Text] [Related]
2. Scientific and Regulatory Considerations in Solid Oral Modified Release Drug Product Development.
Li M; Sander S; Duan J; Rosencrance S; Miksinski SP; Yu L; Seo P; Rege B
AAPS J; 2016 Nov; 18(6):1406-1417. PubMed ID: 27650190
[TBL] [Abstract][Full Text] [Related]
3. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
[TBL] [Abstract][Full Text] [Related]
4. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.
Wang R; Conner DP; Li BV
AAPS J; 2017 Mar; 19(2):360-366. PubMed ID: 28004346
[TBL] [Abstract][Full Text] [Related]
6. In vitro models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
[TBL] [Abstract][Full Text] [Related]
7. IV-IVC considerations in the development of immediate-release oral dosage form.
Li S; He H; Parthiban LJ; Yin H; Serajuddin AT
J Pharm Sci; 2005 Jul; 94(7):1396-417. PubMed ID: 15920764
[TBL] [Abstract][Full Text] [Related]
8. A new roadmap for biopharmaceutical drug product development: Integrating development, validation, and quality by design.
Martin-Moe S; Lim FJ; Wong RL; Sreedhara A; Sundaram J; Sane SU
J Pharm Sci; 2011 Aug; 100(8):3031-3043. PubMed ID: 21425164
[TBL] [Abstract][Full Text] [Related]
9. Regional intestinal drug permeation: biopharmaceutics and drug development.
Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
[TBL] [Abstract][Full Text] [Related]
10. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical quality by design: product and process development, understanding, and control.
Yu LX
Pharm Res; 2008 Apr; 25(4):781-91. PubMed ID: 18185986
[TBL] [Abstract][Full Text] [Related]
12. The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance.
Selen A; Dickinson PA; Müllertz A; Crison JR; Mistry HB; Cruañes MT; Martinez MN; Lennernäs H; Wigal TL; Swinney DC; Polli JE; Serajuddin ATM; Cook JA; Dressman JB
J Pharm Sci; 2014 Nov; 103(11):3377-3397. PubMed ID: 25256402
[TBL] [Abstract][Full Text] [Related]
13. QbD-Enabled Development of Novel Stimuli-Responsive Gastroretentive Systems of Acyclovir for Improved Patient Compliance and Biopharmaceutical Performance.
Singh B; Kaur A; Dhiman S; Garg B; Khurana RK; Beg S
AAPS PharmSciTech; 2016 Apr; 17(2):454-65. PubMed ID: 26238805
[TBL] [Abstract][Full Text] [Related]
14. Paediatric oral biopharmaceutics: key considerations and current challenges.
Batchelor HK; Fotaki N; Klein S
Adv Drug Deliv Rev; 2014 Jun; 73():102-26. PubMed ID: 24189013
[TBL] [Abstract][Full Text] [Related]
15. Biopharmaceutical aspects and implications of excipient variability in drug product performance.
Zarmpi P; Flanagan T; Meehan E; Mann J; Fotaki N
Eur J Pharm Biopharm; 2017 Feb; 111():1-15. PubMed ID: 27845182
[TBL] [Abstract][Full Text] [Related]
16. Human in vivo regional intestinal permeability: importance for pharmaceutical drug development.
Lennernäs H
Mol Pharm; 2014 Jan; 11(1):12-23. PubMed ID: 24206063
[TBL] [Abstract][Full Text] [Related]
17. In vitro-in vivo correlation strategy applied to an immediate-release solid oral dosage form with a biopharmaceutical classification system IV compound case study.
Bredael GM; Bowers N; Boulineau F; Hahn D
J Pharm Sci; 2014 Jul; 103(7):2125-2130. PubMed ID: 24890761
[TBL] [Abstract][Full Text] [Related]
18. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
Heigoldt U; Sommer F; Daniels R; Wagner KG
Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059
[TBL] [Abstract][Full Text] [Related]
19. Application of Absorption Modeling in Rational Design of Drug Product Under Quality-by-Design Paradigm.
Kesisoglou F; Mitra A
AAPS J; 2015 Sep; 17(5):1224-36. PubMed ID: 26002509
[TBL] [Abstract][Full Text] [Related]
20. Biowaiver monographs for immediate-release solid oral dosage forms: stavudine.
Silva AL; Cristofoletti R; Storpirtis S; Sousa VD; Junginger HE; Shah VP; Stavchansky S; Dressman JB; Barends DM
J Pharm Sci; 2012 Jan; 101(1):10-6. PubMed ID: 21922462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
